-
Je něco špatně v tomto záznamu ?
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
T. Tankova, E. Senkus, M. Beloyartseva, S. Borštnar, D. Catrinoiu, M. Frolova, A. Hegmane, A. Janež, M. Krnić, Z. Lengyel, Y. Marcou, L. Mazilu, B. Mrinakova, R. Percik, K. Petrakova, G. Rubovszky, M. Tokar, E. Vrdoljak
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
not applicable
Novartis (Switzerland)
NLK
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
35406370
DOI
10.3390/cancers14071598
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Alpelisib is an α-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression on or after endocrine therapy. Hyperglycemia is an on-target effect of alpelisib affecting approximately 60% of treated patients, and sometimes necessitating dose reductions, treatment interruptions, or discontinuation of alpelisib. Early detection of hyperglycemia and timely intervention have a key role in achieving optimal glycemic control and maintaining alpelisib dose intensity to optimize the benefit of this drug. A glycemic support program implemented by an endocrinology-oncology collaborative team may be very useful in this regard. Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium-glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2-, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.
Department of Endocrinology Medical University of Sofia 2 Zdrave Str 1431 Sofia Bulgaria
Division of Medical Oncology Institute of Oncology Ljubljana Zaloska 2 1000 Ljubljana Slovenia
Faculty of Medicine Ovidius University of Constanta University Alley No 1 900470 Constanta Romania
Masaryk Memorial Cancer Institute Žlutý kopec 543 7 Brno Střed Staré 602 00 Brno Czech Republic
National Institute of Oncology Rath Gy Str 7 9 1122 Budapest Hungary
Sackler Faculty of Medicine Tel Aviv University P O Box 39040 Ramat Aviv Tel Aviv 69978 Israel
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017543
- 003
- CZ-PrNML
- 005
- 20220720100254.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers14071598 $2 doi
- 035 __
- $a (PubMed)35406370
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Tankova, Tsvetalina $u Department of Endocrinology, Medical University of Sofia, 2, Zdrave Str., 1431 Sofia, Bulgaria $1 https://orcid.org/0000000275721131
- 245 10
- $a Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer / $c T. Tankova, E. Senkus, M. Beloyartseva, S. Borštnar, D. Catrinoiu, M. Frolova, A. Hegmane, A. Janež, M. Krnić, Z. Lengyel, Y. Marcou, L. Mazilu, B. Mrinakova, R. Percik, K. Petrakova, G. Rubovszky, M. Tokar, E. Vrdoljak
- 520 9_
- $a Alpelisib is an α-selective phosphatidylinositol 3-kinase inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression on or after endocrine therapy. Hyperglycemia is an on-target effect of alpelisib affecting approximately 60% of treated patients, and sometimes necessitating dose reductions, treatment interruptions, or discontinuation of alpelisib. Early detection of hyperglycemia and timely intervention have a key role in achieving optimal glycemic control and maintaining alpelisib dose intensity to optimize the benefit of this drug. A glycemic support program implemented by an endocrinology-oncology collaborative team may be very useful in this regard. Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium-glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2-, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Senkus, Elżbieta $u Department of Oncology & Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland $1 https://orcid.org/000000016855397X
- 700 1_
- $a Beloyartseva, Maria $u Institution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 23 Kashirskoye Avenue, 115478 Moscow, Russia
- 700 1_
- $a Borštnar, Simona $u Division of Medical Oncology, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia
- 700 1_
- $a Catrinoiu, Doina $u Department of Diabetology, Clinical Emergency Hospital of Constanta, Romania, Tomis Bvd. No. 145, 900591 Constanta, Romania $u Faculty of Medicine, "Ovidius" University of Constanta, University Alley No. 1, 900470 Constanta, Romania
- 700 1_
- $a Frolova, Mona $u Institution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 23 Kashirskoye Avenue, 115478 Moscow, Russia
- 700 1_
- $a Hegmane, Alinta $u Out-Patient Department of Medical Oncology, Riga East University Hospital, Oncology Center of Latvia, 4, Hipokrata Str., LV1079 Riga, Latvia
- 700 1_
- $a Janež, Andrej $u Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Center, Zaloska 7, 1000 Ljubljana, Slovenia
- 700 1_
- $a Krnić, Mladen $u Department of Endocrinology, Clinical Hospital Center Split, School of Medicine, University of Split, Šoltanska 1, 21000 Split, Croatia
- 700 1_
- $a Lengyel, Zoltan $u Szent János Hospital, Diós árok 1-3, 1125 Budapest, Hungary
- 700 1_
- $a Marcou, Yiola $u Medical Oncology Department, The Bank of Cyprus Oncology Centre, 32 Acropoleos Avenue, Strovolos, Nicosia 2006, Cyprus
- 700 1_
- $a Mazilu, Laura $u Department of Diabetology, Clinical Emergency Hospital of Constanta, Romania, Tomis Bvd. No. 145, 900591 Constanta, Romania $u Faculty of Medicine, "Ovidius" University of Constanta, University Alley No. 1, 900470 Constanta, Romania $1 https://orcid.org/0000000161954500
- 700 1_
- $a Mrinakova, Bela $u 1st Department of Oncology, Comenius University, Faculty of Medicine, Bratislava, Heydukova 10, 812 50 Bratislava, Slovakia $u Slovak Republic Department of Medical Oncology, St. Elisabeth Cancer Institute, Heydukova 10, 812 50 Bratislava, Slovakia $1 https://orcid.org/0000000197950640
- 700 1_
- $a Percik, Ruth $u Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Ramat Gan 52621, Israel $u Sackler Faculty of Medicine, Tel Aviv University, P.O. Box 39040, Ramat Aviv, Tel Aviv 69978, Israel
- 700 1_
- $a Petrakova, Katarina $u Masaryk Memorial Cancer Institute, Žlutý kopec 543/7, Brno-Střed-Staré, 602 00 Brno, Czech Republic
- 700 1_
- $a Rubovszky, Gábor $u National Institute of Oncology, Rath Gy. Str. 7-9, 1122 Budapest, Hungary
- 700 1_
- $a Tokar, Margarita $u The Legacy Heritage Oncology Center and Dr. Larry Norton Institute, SorokaMedical Center, Yitzhack I. Rager Blvd 151, Be'er Sheva, Israel
- 700 1_
- $a Vrdoljak, Eduard $u Department of Oncology, Clinical Hospital Center Split, School of Medicine, University of Split, Spinčićeva 1, 21000 Split, Croatia
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 7 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35406370 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100250 $b ABA008
- 999 __
- $a ind $b bmc $g 1816640 $s 1168785
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 7 $e 20220322 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a not applicable $p Novartis (Switzerland)
- LZP __
- $a Pubmed-20220718
